GlassScriptPhysician profile
Chelsea E Presson
NPI 1548749906
$22,052.27
in general payments reported to CMS, 2019-2025
36 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $72.26 · 2023: $1,707 · 2024: $4,354 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,233 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,365 · Travel and Lodging: $3,011 · Consulting Fee: $2,075 · Education: $35.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,233.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,365.00 |
| Travel and Lodging | $3,010.50 |
| Consulting Fee | $2,075.00 |
| Education | $35.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,535.73 | 2023-2025 | |
| Argenx US, INC. | $2,914.80 | 2024-2025 | Vyvgart Hytrulo |
| Abbvie INC. | $2,371.66 | 2021-2025 | |
| Ucb, INC. | $930.44 | 2023-2025 | Rystiggo, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $753.92 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $502.47 | 2023-2025 | Rytary, Crexont, Lyvispah |
| Lundbeck LLC | $460.85 | 2023-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $352.43 | 2023-2025 | Ultomiris, Soliris |
| Mdd US Operations, LLC | $323.30 | 2023-2025 | Apokyn, Gocovri |
| Merz Pharmaceuticals, LLC | $306.29 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Csl Behring | $303.22 | 2025 | Hizentra |
| Biogen, INC. | $244.05 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Biohaven Pharmaceuticals, INC. | $240.13 | 2021 | |
| Lilly USA, LLC | $235.74 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Amgen INC. | $225.08 | 2023-2025 | Uplizna, Aimovig |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $133.80 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Springworks Therapeutics, INC. | $124.92 | 2025 | Gomekli |
| Eisai INC. | $120.65 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $100.63 | 2024-2025 | Dysport |
| Celgene Corporation | $98.36 | 2024-2025 | Zeposia |
| Impel Pharmaceuticals INC. | $83.02 | 2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $78.18 | 2023-2025 | Ingrezza, Ongentys |
| Livanova USA, INC. | $75.61 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $73.81 | 2025 | |
| Genzyme Corporation | $73.79 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.26 | 2022 | |
| Tanabe Pharma America, INC. | $62.16 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $61.89 | 2023-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $39.36 | 2025 | Hyqvia |
| Sk Life Science, INC. | $31.36 | 2025 | |
| Mallinckrodt Hospital Products INC. | $25.05 | 2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $22.69 | 2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $22.51 | 2025 | Wainua |
| Jazz Pharmaceuticals INC. | $21.14 | 2025 | |
| Ns Pharma, INC. | $15.90 | 2025 | Viltepso |
| Averitas Pharma INC. | $15.07 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Presson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.